Tirzepatide is a novel dual agonist that targets both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor ( 2 Literature search strategy This narrative review aimed to synthesize current mechanistic and clinical evidence regarding tirzepatide in obesity-related OSAS
PT-141 comes in three forms: a subcutaneous injection, a nasal spray, and a sublingual tablet
The importance of cost in discontinuation was also reflected in clinical notes data
Be sure to tell your healthcare provider about all medications you are taking
This growth is driven by the increasing prevalence of type 2 diabetes and obesity, with GLP-1 receptor agonists offering effective treatment options that help manage blood sugar levels, promote weight loss, and reduce cardiovascular risks
Myosteatosis alters muscle fiber composition and organization, with a decrease in oxidative, insulin-sensitive fibers and a concomitant increase in relatively fast-fatiguing glycolytic fibers, paralleling the effects observed in obesity and aging